NasdaqCM - Delayed Quote USD

Biofrontera Inc. (BFRI)

0.9900 -0.0300 (-2.94%)
At close: June 7 at 4:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
33,250.0000
34,071.0000
28,674.0000
24,100.0000
18,849.0000
--
Cost of Revenue
16,962.0000
17,444.0000
15,185.0000
12,742.0000
9,066.0000
--
Gross Profit
16,288.0000
16,627.0000
13,489.0000
11,358.0000
9,783.0000
--
Operating Expense
38,640.0000
39,204.0000
35,870.0000
37,209.0000
18,117.0000
--
Operating Income
-22,352.0000
-22,577.0000
-22,381.0000
-25,851.0000
-8,334.0000
--
Net Non Operating Interest Income Expense
-1,932.0000
-560.0000
-203.0000
-344.0000
-2,869.0000
--
Other Income Expense
1,204.0000
3,020.0000
21,976.0000
-11,462.0000
280.0000
--
Pretax Income
-23,080.0000
-20,117.0000
-608.0000
-37,657.0000
-10,923.0000
--
Tax Provision
10.0000
14.0000
32.0000
56.0000
64.0000
--
Net Income Common Stockholders
-23,090.0000
-20,131.0000
-640.0000
-37,713.0000
-10,987.0000
--
Diluted NI Available to Com Stockholders
-23,090.0000
-20,131.0000
-640.0000
-37,713.0000
-10,987.0000
--
Basic EPS
-10.30
--
-0.61
-85.60
-18.94
-18.93
Diluted EPS
-10.30
--
-0.61
-85.60
-18.94
-18.93
Basic Average Shares
2,118.4580
--
1,056.9880
440.4110
580.0000
580.0000
Diluted Average Shares
2,118.4580
--
1,056.9880
440.4110
580.0000
580.0000
Total Operating Income as Reported
-22,652.0000
-22,677.0000
-18,581.0000
-25,201.0000
-9,606.0000
--
Total Expenses
55,602.0000
56,648.0000
51,055.0000
49,951.0000
27,183.0000
--
Net Income from Continuing & Discontinued Operation
-23,090.0000
-20,131.0000
-640.0000
-37,713.0000
-10,987.0000
--
Normalized Income
-23,606.0000
-22,413.3100
-17,946.5300
-28,842.7700
-10,019.7407
--
Interest Income
90.0000
132.0000
175.0000
16.0000
28.0000
--
Interest Expense
1,930.0000
600.0000
370.0000
360.0000
2,897.0000
--
Net Interest Income
-1,932.0000
-560.0000
-203.0000
-344.0000
-2,869.0000
--
EBIT
-21,150.0000
-19,517.0000
-238.0000
-37,297.0000
-8,026.0000
--
EBITDA
-20,045.0000
-18,453.0000
934.0000
-36,757.0000
-7,464.0000
--
Reconciled Cost of Revenue
16,962.0000
17,444.0000
15,185.0000
12,742.0000
9,066.0000
--
Reconciled Depreciation
1,105.0000
1,064.0000
1,172.0000
540.0000
562.0000
--
Net Income from Continuing Operation Net Minority Interest
-23,090.0000
-20,131.0000
-640.0000
-37,713.0000
-10,987.0000
--
Total Unusual Items Excluding Goodwill
860.0000
2,889.0000
21,907.0000
-12,151.0000
-973.0000
--
Total Unusual Items
860.0000
2,889.0000
21,907.0000
-12,151.0000
-973.0000
--
Normalized EBITDA
-20,905.0000
-21,342.0000
-20,973.0000
-24,606.0000
-6,491.0000
--
Tax Rate for Calcs
0.0004
0.0002
0.0002
0.0003
0.0000
--
Tax Effect of Unusual Items
344.0000
606.6900
4,600.4700
-3,280.7700
-5.7407
--
12/31/2019 - 10/29/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PTPI Petros Pharmaceuticals, Inc.
0.4820
-3.41%
 
SHPH Shuttle Pharmaceuticals Holdings, Inc.
0.4650
+0.89%
 
SNOA Sonoma Pharmaceuticals, Inc.
0.2050
+6.99%
 
DERM Journey Medical Corporation
4.7000
+0.43%
 
SXTC China SXT Pharmaceuticals, Inc.
1.1350
+0.44%
 
ALKS Alkermes plc
23.91
-1.03%
 
AKAN Akanda Corp.
2.2200
-9.76%
 
IXHL Incannex Healthcare Inc.
3.2500
+2.20%
 
SBFM Sunshine Biopharma, Inc.
0.5579
+5.26%
 
CLSH CLS Holdings USA, Inc.
0.0500
0.00%